Please select the option that best describes you:

How do you approach the decision to boost patients diagnosed with DCIS?  

What factors do you consider?

Is your thought process at all different from your approach to boost with IDC? 

Do you apply TROG 7.01 data (age <50 or at least one of: palpable tumor, multifocal disease, ≥1.5cm, G2-3, central necrosis, comedo histology, and margins <1cm) had improved 5-yr freedom-from-local-recurrence with the addition of boost?

For additional reading, see JCO OGR 11/2021 by @Laura Warren and @Jennifer R. Bellon reviewing landscape of adjuvant treatment after lumpectomy for DCIS, and companion study with longterm outcomes from RTOG 9804 (@Beryl McCormick et al). 



Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Inspira Medical Center
@Sushil Beriwal - Thanks for the abstract. Like y...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
I use hypofractionation so use 10 in 4. In the ab...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Angelhaven LLC
An older study (Lalani et al., PMID 25220719 or Wi...
Sign in or Register to read more